Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie
| Autor: | Romain Geiss, Anne Vincent-Salomon, Coralie Franck, Miguelle Marous, Elvire Pons Tostivint, Sophie Gardrat, Benjamin Bonsang, Céline Callens, Roman Rouzier, Guillaume Bataillon, Samia Melaabi, Nathalie Clément, Vincent Servois, P. Tresca, Choumouss Kamoun, Julien Masliah-Planchon, Ivan Bièche, Gaëlle Pierron, Elodie Girard, Odette Mariani, Claire Morel, Maud Kamal, Christophe Le Tourneau, Camille Benoist, Clémence Basse, Marie Alt, Marion Lavigne, Delphine Loirat, G Schleiermacher, Coraline Dubot, Pauline Vaflard, Marie Paule Sablin, Maude Ardin, Virginie Bernard |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Targeted therapy 03 medical and health sciences 0302 clinical medicine Internal medicine Biopsy medicine Tumor board Original Research clinical trials medicine.diagnostic_test Molecular screening business.industry targeted therapy Clinical trial molecular tumour board tumour profiling 030104 developmental biology Median time 030220 oncology & carcinogenesis Fresh frozen Archival tissue business |
| Zdroj: | ESMO Open |
| ISSN: | 2059-7029 |
| Popis: | Background High throughput molecular screening techniques allow the identification of multiple molecular alterations, some of which are actionable and can be targeted by molecularly targeted agents (MTA). We aimed at evaluating the relevance of using this approach in the frame of Institut Curie Molecular Tumor Board (MTB) to guide patients with cancer to clinical trials with MTAs. Patients and methods We included all patients presented at Institut Curie MTB from 4 October 2014 to 31 October 2017. The following information was extracted from the chart: decision to perform tumour profiling, types of molecular analyses, samples used, molecular alterations identified and those which are actionable, and inclusion in a clinical trial with matched MTA. Results 736 patients were presented at the MTB. Molecular analyses were performed in 442 patients (60%). Techniques used included next-generation sequencing, comparative genomic hybridisation array and/or other techniques including immunohistochemistry in 78%, 51% and 58% of patients, respectively. Analyses were performed on a fresh frozen biopsy in 91 patients (21%), on archival tissue (fixed or frozen) in 326 patients (74%) and on both archival and fresh frozen biopsy in 25 patients (6%). At least one molecular alteration was identified in 280 analysed patients (63%). An actionable molecular alteration was identified in 207 analysed patients (47%). Forty-five analysed patients (10%) were enrolled in a clinical trial with matched MTA and 29 additional patients were oriented and included in a clinical trial based on a molecular alteration identified prior to the MTB analysis. Median time between date of specimen reception and molecular results was 28 days (range: 5–168). Conclusions The implementation of an MTB at Institut Curie enabled the inclusion of 10% of patients into a clinical trial with matched therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|